74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis by Delabaye, Isabelle & De Keyser, Filip
Delabaye et al. Arthritis Research & Therapy 2010, 12:R121
http://arthritis-research.com/content/12/3/R121
Open AccessR E S E A R C H  A R T I C L EResearch article74-week follow-up of safety of infliximab in 
patients with refractory rheumatoid arthritis
Isabelle Delabaye1,3, Filip De Keyser*2 for the REMITRACT study group
Abstract
Introduction: The objective was to describe the prevalence, types, and predictors of adverse events (AEs) in 
rheumatoid arthritis (RA) patients treated with infliximab and methotrexate in a daily clinical setting.
Methods: This was a prospective, multi-center, open-label, 74-week observational study in patients with active RA 
despite treatment with methotrexate and at least one other disease-modifying anti-rheumatic drug. Patients were 
treated with 3 mg/kg infliximab at weeks 0, 2, and 6 and then every 8 weeks. At weeks 0, 6, 26, 50, and 74, patients 
answered a health assessment questionnaire, a swollen joint count was made, and adverse events (AEs) occurring 
during the previous period were registered.
Results: Five hundred and seventy-five patients were treated with infliximab, of which 346 were still on infliximab at 
the study end, 158 discontinued treatment, and 71 were lost to follow-up. Reasons for discontinuation included safety 
(n = 74), elective reasons (n = 43), and inefficacy (n = 41). Infusion reactions (n = 33) and infections (n = 20) were the 
most common AEs causing discontinuation and the most common AEs overall. There were four cases of tuberculosis, 
all of which occurred in patients negative at screening. Total AEs, serious AEs, and infusion reactions as well as 
discontinuations for AEs were most frequent during the first 26 weeks. Higher age was a predictor of serious adverse 
events (SAEs), infection, and discontinuation due to an SAE, but odds ratios were close to one.
Conclusions: AEs and discontinuations due to AEs occur most frequently during the first half year of infliximab 
treatment in refractory RA patients. The main reasons for discontinuing treatment are infections and infusion reactions. 
Tuberculosis and other infections remain an important concern in these patients.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disorder of unknown etiology that occurs in
approximately 0.8% of the population [1]. Initial therapy
for RA has included non-steroidal anti-inflammatory
drugs (NSAIDs), ultimately giving way to oral steroids
and disease-modifying antirheumatic drugs (DMARDs).
More recent practice is to initiate DMARDs early [2-4].
Methotrexate (MTX) has become the DMARD of choice
because of its relatively rapid mode of action and good
control during prolonged use; however, for many
patients, MTX provides only partial relief of signs and
symptoms [5].
The development of biological agents targeting the
interaction between effector cells has been a major
advance in the treatment of RA [1]. Many of these biolog-
ical agents act by neutralizing TNF-α, which plays a cen-
tral role in the chronic inflammation and tissue damage
of RA [6]. Infliximab is a monoclonal antibody that binds
with high affinity and specificity to human TNF and neu-
tralizes its biologic activity [7]. To date, four double-
blind, placebo-controlled, randomized studies have been
completed in patients with active RA despite DMARD
therapy [8-11]. These studies have shown clinical
response rates of 40% to 60% in patients treated with a
combination of MTX and infliximab.
The most common adverse events (AEs) found in clini-
cal trials of infliximab include upper respiratory tract
infection, headache, nausea, sinusitis, rash, pharyngitis,
and cough, with infusion reactions (IRs) reported in 5%
to 20% of patients [9,12]. Although the clinical trials did
not show a significant increase in the risk of infections
with the use of infliximab, a meta-analysis of randomized
clinical studies found a significantly higher rate of serious
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Page 2 of 12infections [13]. Also, some reports have suggested an
increased risk of malignancies, especially lymphoma, in
RA patients treated with anti-TNF-α therapies [13-15],
but this has been refuted by several recent studies [16-
18]. Several observational and retrospective studies have
shown that, in daily practice, up to one-fourth or one-
third of patients discontinue infliximab within one year
and that roughly one-third of discontinuations are due to
AEs, with IRs the most common type causing discontinu-
ation [19-21].
Here, we performed a multi-center, prospective, obser-
vational study on the safety of infliximab in combination
with MTX. The aims of this study were to describe the
prevalence and types of AEs and identify predictors of
AEs and treatment discontinuation. This information
should provide expanded data to health care workers and
authorities to help estimate and support the appropriate
use of infliximab.
Materials and methods
Study design and patient selection
This was a prospective, multi-center, open-label, observa-
tional study of infliximab in the treatment of patients
with active RA despite treatment with MTX and at least
one other DMARD. The study was carried out at 77 cen-
ters in Belgium between July 2002 and June 2006. The
protocol was approved by the ethics committees of the
participating study centers, and the study was conducted
in accordance with the Declaration of Helsinki. Prior to
initiating treatment, written informed consent was
obtained from all patients by the treating physician using
a form approved by the ethics committees. The study was
not registered because it was purely observational and
was started in 2002.
Patients eligible for this study had to be diagnosed with
erosive RA and have evidence of active disease despite
treatment with MTX and at least one other DMARD. Eli-
gible patients also had to be on a stable dose of 15 mg/wk
or more of MTX given orally or parenterally for at least
three months. Patients with intolerance to MTX despite
the association with folic acid could also be included.
Additional inclusion criteria were as follows: men or
women 17 years or older; 8 or more swollen joints; Health
Assessment Questionnaire (HAQ) index of 25 or more
(HAQ score × 10 ÷ 6); and absence of tuberculosis dem-
onstrated by simultaneous negative Mantoux test and
negative chest X-ray. In the case of a positive Mantoux
test or X-ray, the patient had to have had adequate treat-
ment of the tuberculosis for six months before treatment
with infliximab. Women of childbearing potential had to
be using adequate birth control measures.
Exclusion criteria were as follows: women pregnant,
nursing, or planning a pregnancy within two years of
enrollment; a history of known allergies to murine pro-
teins; serious infections, such as hepatitis, pneumonia,
and pyelonephritis in the previous three months; history
of opportunistic infections such as herpes zoster within
two months of screening; evidence of active cytomegalo-
virus, active Pneumocystis carinii, drug-resistant atypical
mycobacterium, or other opportunistic infections; docu-
mented infection with HIV; current signs or symptoms of
severe, progressive, or uncontrolled renal, hepatic, hema-
tologic, endocrine, pulmonary, cardiac, neurologic, or
cerebral disease; previous or concurrent malignancies,
with the exception of surgically cured carcinoma in situ
of the cervix and surgically cured basal or squamous cell
carcinoma of the skin; alcoholism, alcoholic liver disease,
or other chronic liver disease; and congestive heart failure
grade III and IV.
Treatments
Treatment was initiated in eligible patients within four
weeks of the screening visit. Patients received an infusion
of 3 mg/kg infliximab (Remicade®; Centocor, Leiden, The
Netherlands) at weeks 0, 2, and 6 and then every 8 weeks.
Dose escalations or shortening of treatment intervals
were not permitted.
Clinical evaluations
At screening, demographic data and medical history were
obtained, and the patient underwent a physical examina-
tion, had routine baseline (hematology and chemistry)
exams, a chest X-ray, and a Mantoux test. At screening
and at weeks 6, 26, 50, and 74 after the start of treatment,
patients completed a HAQ [22]. In addition, a swollen
joint count (SJC) based on 66 joints was determined [23].
Concurrent medications were recorded at weeks 6, 26,
50, and 74.
Safety evaluations
Safety data were collected at weeks 6, 26, 50, and 74 for
events occurring during weeks 0 to 6, 7 to 26, 27 to 50,
and 51 to 74, respectively. A serious adverse event (SAE)
was defined as any AE that resulted in death, was life-
threatening, resulted in a persistent or significant disabil-
ity or incapacity, required hospitalization or prolonged a
hospitalization, or resulted in a congenital anomaly or
birth defect. Also, important medical events that may not
have resulted in death, were not life-threatening, or did
not require hospitalization may have been considered a
SAE when, according to the investigator, they jeopardized
the subject or required medical or surgical intervention
to prevent one of the outcomes defining a SAE. An IR was
defined as any AE that occurred during an infusion,
within one hour after an infusion, or was considered by
the investigator to be infusion-related. For each time
period, the presence or absence of IRs was recorded only
once.
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Descriptive statistics were used for groups with and with-
out AEs, SAEs, and IRs. T-tests were used to examine dif-
ferences in the age, age at diagnosis, severity (HAQ index
and SJC), the dose of MTX, and the duration of disease
between the patients with AEs or SAEs and the patients
who had no AEs or SAEs. Fisher's Exact Tests (or chi
square tests) were used to look for association between
the presence of an AE/SAE and the use of corticosteroids,
the use of MTX, and sex. Logistic (stepwise) regression
analysis was used to assess the ability of baseline charac-
teristics to predict the manifestation of AEs, SAEs, or
infections. Fisher's exact test was used to examine the
association between the use of corticosteroids and the
manifestation of an infection. Means are presented ±
standard deviations, and odds ratios are given with 95%
confidence intervals (CI).
Results
Baseline demographics and patient disposition
A total of 596 patients were screened for this study. Of
the 596 screened patients, 575 started infliximab. There
were 71 losses to follow-up, so that 504 patients were
evaluable (Figure 1a). Of these, 158 discontinued inflix-
imab before week 74, and the remaining 346 patients
were still on infliximab according to protocol at week 74.
The baseline demographics of the patients receiving at
least one dose of infliximab are shown in Table 1. Nearly
three-quarters of the patients (n = 419; 72.9%) were
female. The mean age of patients was 57 ± 13 years, and
the mean duration of disease was 10.3 ± 9.4 years. The
mean HAQ index at screening was 56.1 ± 15.4, and the
mean SJC at screening was 16.3 ± 7.5. Almost all patients
(n = 537; 93.4%) were taking MTX, and the mean MTX
dose was 14.5 mg/week.
Efficacy of therapy
Efficacy of the treatment was assessed using the HAQ
and by counting the number of swollen joints. The mean
HAQ index decreased from 56.0 ± 15.4 at baseline to 29.0
± 21.4 at week 74 (P < 0.0001), and the SJC decreased
from 16.3 ± 7.5 at baseline to 3.2 ± 4.0 at week 74 (P <
0.0001).
Adverse events
A total of 338 AEs were registered during the study. Of
these, 121 (35.8%) were considered SAEs (Table 2). The
highest number of AEs occurred during the first 26 weeks
of treatment with infliximab (Figure 2a). Thereafter, the
incidence of AEs decreased gradually over time. Similarly,
AEs considered serious (SAEs) were most common dur-
ing the first 26 weeks.
As detailed in Table 2, infection was the most com-
monly reported type of AE (n = 93), followed by IRs (n =
77). Other common (>5%) AEs included dermatological
reactions (n = 40), cardiovascular disorders (n = 22), RA-
related disease manifestations (n = 17), and gastrointesti-
nal disorders (n = 17). The most common SAE was infec-
tion (n = 47), followed by IRs (n = 15), cardiovascular
events (n = 15), and RA-related disease manifestations (n
= 11).
There were 93 reported infections in 81 patients. Infec-
tions were most common during the first 26 weeks of the
study (Figure 2b). Approximately half (n = 47) of the
infections were reported as SAEs (Table 2). For cases
where the infectious agent was known, the most common
type was non-tuberculosis-type bacteria (n = 38). Tuber-
culosis accounted for four of the infections (three con-
firmed, one suspected), all of which were considered
SAEs. One was a confirmed case of unspecified tubercu-
losis in a 28-year-old woman who had been exposed to a
family member with an overt tuberculosis infection. The
remaining two confirmed cases were pulmonary tubercu-
losis in a 38-year-old woman and a 43-year-old man who
did not have known exposure to overt tuberculosis. The
fourth case was suspected tuberculosis meningitis in a
69-year-old man that was not confirmed by laboratory
tests and later had a differential diagnosis of viral menin-
gitis. All four reported cases of tuberculosis were in
patients taking corticosteroids at baseline. Further details
about the cases of tuberculosis are presented in the Sup-
porting information in Additional file 1.
The 77 reported IRs occurred in 64 patients. Fifteen of
these IRs were recorded as SAEs, and 33 led to treatment
discontinuation. Overall, the highest incidence of IRs and
the highest incidence of IRs leading to discontinuation
occurred during the first 26 weeks (Figure 2c). The most
common specific symptoms associated with IRs were
allergic skin reactions (n = 24) and hemodynamic events
(n = 16; Table 3). Both allergic skin reactions and hemo-
dynamic events were most frequent during the first 26
weeks (i.e., following infusion at weeks 6, 14, and 22).
Other common IRs (>5%) included hyperventilation/dys-
pnea (n = 13), flushing (n = 7), hypertension (n = 6),
tachycardia/palpitation (n = 5), and headache (n = 4), all
of which were most frequent during the first 26 weeks of
treatment.
During the study, seven tumors were reported in seven
patients (Table 2). Four of the tumors were malignant
(one epidermoid epithelioma of the right lung, one lung
cancer, one carcinoma in situ of the cervix, and one case
of chronic myelomonocytic leukemia). Tumors led to dis-
continuation of treatment in five cases. Further details
about these cases are presented in the Supporting infor-
mation in Additional file 1.
There were 22 cardiovascular disorders reported dur-
ing the study, 15 of which (68.2%) were considered SAEs.
Four of these events led to discontinuation, including one
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Figure 1 Patient disposition. (a) Flow chart of patient disposition. A total of 596 patients were screened for this study, of which 575 started infliximab. 
Of these, 71 were lost to follow-up, so that 504 were evaluated. There were 158 patients that discontinued treatment before week 74, and the remain-
ing 346 completed the study according to protocol and were still on infliximab at study end. 'Other' under treatment discontinuations included three 
patients that wished to become pregnant and one that withdrew prior to an elective surgery. (b) Patients remaining on infliximab at each visit. (c) 
Fraction of evaluable patients completing the study or discontinuing for safety reasons, inefficacy, or elective reasons.
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Page 5 of 12pulmonary thromboembolism, one case of cardiac isch-
emia, and two fatal events (one myocardial infarct and
one cardiac arrest). Of the dermatological and gastroin-
testinal disorders reported, most (38/40 (95%) and 16/17
(94.1%), respectively) were not considered SAEs.
There were a total of nine deaths during the study,
including five for which the main cause of death was
infection (three bacterial, one other opportunistic infec-
tion, and one unknown type), two due to cardiovascular
events (one cardiac arrest and one myocardial infarct),
one due to a traumatic event (traffic accident), and one
due to a psychiatric disorder (suicide). All patients that
died for health reasons were at least 69 years old at the
time of death. Details about the deaths occurring during
this study are provided in the Supporting information in
Additional file 1.
Treatment discontinuations
The number of patients remaining in the study at each
visit is shown in Figure 1b. Of the 504 evaluable patients,
a total of 158 (31.3%) discontinued treatment before week
74, so that the continuation rate at the end of the study
was 68.7% (Figure 1c). The leading reason for discontinu-
ation was safety (n = 74; 14.7% of evaluable patients). Dis-
continuation due to inefficacy occurred in 41 cases (8.1%;
Figure 1c). The remaining discontinuations (n = 43; 8.5%)
were due to elective reasons, including withdrawal of
consent (n = 17), noncompliance with the study protocol
(n = 22), wish for pregnancy (n = 3), and wish to stop
prior to an elective surgery (n = 1). Of the 74 discontinua-
tions for safety, the majority (n = 47) were for SAEs,
although many (n = 27) were for AEs that were not seri-
ous (Figure 1a). Treatment discontinuations overall and
for safety or inefficacy were most common during the
first 26 weeks (Figure 3).
The AEs most commonly leading to discontinuation
were IRs (n = 33), infections (n = 20), tumors (n = 5 (2
benign and 3 malignant)), cardiovascular events (n = 4),
and dermatological disorders (n = 4; Table 2). There was a
significant association between the occurrence of an AE
and discontinuation due to the AE for IRs (P < 0.0001),
tuberculosis (P = 0.034), tumors (P = 0.0065), and malig-
nant tumors (P = 0.034). Non-serious AEs leading to dis-
continuation included IRs (n = 21), dermatological
disorders (n = 3), neurological (optical neuritis) disorders
(n = 1), psychiatric disorders (n = 1), and RA-related
symptoms (n = 1).
Predictors of adverse events, infusion reactions, and 
treatment discontinuation
Statistical tests were used to determine whether baseline
demographics (age at screening, age at diagnosis, dura-
tion of disease, HAQ index, SJC, sex, use of corticoster-
oids, and dose of MTX) were associated with or could
Table 1: Baseline demographics of patients receiving at 
least one dose of infliximab
Characteristic Value
Age (years) (n = 575)
Mean ± SD 57 ± 13
Median 58
Range 19 -99
Sex
Female, N (%) 419 (72.9%)
Male, N (%) 156 (27.1%)
Age at diagnosis (years) (n = 564)
Mean ± SD 46.2 ± 13.6
Median 47
Range 5-81
Duration of disease (years) (n = 564)
Mean ± SD 10.3 ± 9.4
Median 8
Range 0-53
HAQ index at screening (n = 573)
Mean ± SD 56.1 ± 15.4
Median 55
Range 2-98
Swollen joint count at screening (n = 568)
Mean ± SD 16.3 ± 7.5
Median 14
Range 0-49
MTX doses in mg/week (n = 425)
Mean ± SD 14.5 ± 3.0
Median 15
Range 5-25
MTX use
Yes, N (%) 537 (93.4%)
No, N (%) 14 (2.4%)
Unknown, N (%) 24 (4.2%)
NSAID use
Yes, N (%) 414 (72%)
No, N (%) 46 (8%)
Unknown, N (%) 115 (20%)
Corticosteroid use
Yes, N (%) 341 (59.3%)
No, N (%) 84 (14.6%)
Unknown, N (%) 150 (26.1%)
HAQ, health assessment questionnaire; MTX, methotrexate; 
NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard 
deviation.
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IRs or the discontinuation of treatment. Higher age at
screening was significantly associated with (P = 0.043)
AEs. In addition, higher age was a predictor of the mani-
festation of AEs (P = 0.0016), infection (P = 0.018), and
discontinuation due to an SAE (P = 0.0017), but the odds
ratios were all close to 1.0 (1.047 (95% CI, 1.018 to
1.077)), 1.047 (95% CI, 1.008 to 1.087), and 1.076 (95% CI,
1.028 to 1.127), respectively). Neither corticosteroid use
nor any of the other baseline variables besides age was
associated with or was predictive (P > 0.05) of the occur-
rence of AEs overall, SAEs, infections, IRs, or discontinu-
ation for AEs, SAEs, IRs, or inefficacy.
Discussion
This was a 74-week prospective study on the safety of inf-
liximab in patients that had active RA despite treatment
with MTX and at least one other DMARD. This study
was longer than most randomized clinical trials that have
examined the safety of infliximab (mean 0.8 years) [16].
In this study, the most common reason for discontinuing
treatment was an AE, of which infections and IRs were
the most frequent causes. We also found that AEs as well
as discontinuations for AEs most often occurred during
the first 26 weeks of treatment.
Our study confirmed that infections are the most com-
mon type of AE in RA patients receiving the combination
of infliximab and MTX [20,24,25]. Approximately half of
all infections were considered SAEs, and infections were
also the most common type of SAE. The rate of infections
considered SAEs in this study (7.4%; (42 of 575 patients))
was similar to that reported using the same dose of inflix-
imab in ATTEST (Abatacept or infliximab vs placebo, a
Trial for Tolerability, Efficacy and Safety in Treating rheu-
matoid arthritis) (8.5%) [26]. In addition, after IRs, infec-
tions were the second leading cause of discontinuation.
Table 2: Types and severity of adverse events
All AEs SAEs AEs Leading to discontinuation
Any 338 (168) 121 (89) 74
Infection 93 (81) 47 (42) 20
Tuberculosisa 4 (4) 4 (4) 3
Other bacterial Infection 38 (33) 29 (24) 10
Viral Infection 8 (8) 5 (5) 1
Opportunistic infectiona 8 (8) 3 (3) 2
Other 35 (32) 6 (6) 4
Infusion reactionb 77 (64) 15 (15) 33
Dermatological disorders 40 (33) 2 (2) 4
Cardiovascular disorders 22 (20) 15 (13) 4
RA-related disease manifestations 17 (16) 11 (11) 2
Gastrointestinal disorders 17 (16) 1 (1) -
Respiratory disorders 11 (10) 4 (4) -
Neurologic disorder 11 (10) 1 (1) 1
Non-RA joint manifestations 8 (8) 4 (4) -
Tumora 7 (7) 6 (6) 5
Benign 3 (3) 2 (2) 2
Malignant 4 (4) 4 (4) 3
Traumatic event 7 (7) 4 (4) 1
Hematologic disorders 4 (4) 4 (4) 1
Psychiatric disorders 3 (3) 1 (1) 2
Liver toxicities 2 (2) 1 (1) -
Other 19 (16) 5 (5) 1
Values are numbers of AEs, with the number of patients affected shown in parentheses.
a See Supporting information in Additional file 1 for further details.
b Individual infusion reactions are described in Table 3.
AE, adverse event; RA, rheumatoid arthritis; SAE, serious adverse event.
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Figure 2 Incidence of (a) AEs, (b) infections, and (c) IRs during the study. The incidence of (a) all adverse events (AEs), (b) infections, and (c) in-
fusion reactions (IRs) are shown for weeks 0 to 26, 27 to 50, and 51 to 74. The week 0 to 26 values were calculated by summing the number events for 
weeks 0 to 6 and weeks 7 to 26. For each time period, the presence or absence of IRs was recorded only a single time. However, this did not affect the 
calculation of the week 0 to 26 value from the week 0 to 6 and week 7 to 26 values.
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common type of infection was non-tuberculosis bacteria,
although viral infections were also common. This agrees
with data from the Swedish practice-based registry
ARTIS (AntiRheumatic Therapies In Sweden), which
indicate that there is a slight increase in the risk of infec-
tion in RA patients treated with anti-TNF-α agents but
that it is not driven by any particular type of infection
[27]. A recent meta-analysis of randomized clinical trials
by Leombruno and colleagues, however, did not find an
increased risk of serious infections in RA patients treated
with recommended doses of anti-TNF-α therapies [16].
Similar to Takeuchi and colleagues [28], we found that
older patients were more likely to have infections,
although the odds ratio was close to 1.0. It is also note-
worthy that all patients that died from infections were at
least 69 years old. Finally, although our study confirms
that infections are a reason for concern in refractory RA
patients, we cannot determine whether the risk for infec-
tion or death due to an infection was increased by treat-
ment with infliximab.
With regard to infections, of particular concern is the
increased risk for tuberculosis in patients treated with
infliximab, which is generally thought to be due to a lack
of compliance with recommendations to prevent reacti-
vation of latent tuberculosis infections [29,30]. In the cur-
rent study, there were four cases of tuberculosis (three
confirmed, one suspected). All four were in patients with
negative Mantoux tests and chest X-rays at screening.
One of the confirmed cases of tuberculosis appeared to
be a new case caused by exposure to a family member
with overt tuberculosis. The remaining could have been
new cases of tuberculosis, but they may have also been
due to latent infections that went undetected by the
screening tests [30]. Interestingly, all four cases of tuber-
culosis were in patients taking corticosteroids at baseline,
which could have masked the Mantoux test or caused
further suppression of the patient's immune system.
Regardless of the reasons for these infections, we concur
Table 3: Infusion-related events and symptoms
Week 0 to 6 Week 7 to 26 Week 27 to 50 Week 51 to 74 Total
Infusion-related eventsa 23 28 15 11 77
Symptom
Allergic skin reaction 2 13 6 3 24
Hemodynamic events (hypotension, 
syncope, bradycardia, cyanosis)
4 8 2 2 16
Hyperventilation/dyspnea 1 5 5 2 13
Flushing 0 4 2 1 7
Hypertension 2 3 0 1 6
Tachycardia/palpitation 2 2 1 0 5
Headache 1 1 1 1 4
Throat, Quincke's, or mouth edema 0 2 1 0 3
Polyathralgia 2 0 0 1 3
Limb edema 1 1 0 0 2
Flu-like symptom 2 0 0 0 2
Allergic reaction, unspecified 1 0 0 0 1
Other 9 8 5 4 26
a Each infusion reactions could result in multiple symptoms so that the total number of symptoms (n = 112) exceeded the number of infusion-
related events (n = 77).
Figure 3 Treatment discontinuations over time.
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despite screening and efforts to treat latent infections, cli-
nicians need to carefully monitor for the emergence of
tuberculosis infections in patients receiving anti-TNF-α
therapies.
In addition to infection, IRs are common in patients
treated with anti-TNF-α therapies and are a frequent rea-
son for discontinuation [31]. In this study, IRs were the
second-most common type of AE. In nearly half of these
cases (42.8%), the IRs caused treatment discontinuation,
although, in many cases, the IR causing discontinuation
was not considered an SAE. In agreement with
Kapetanovic and colleagues [32], age, sex, and HAQ
results were not risk factors for IRs. In contrast to their
report, however, we did not find an association between
IRs and age at diagnosis/onset or longer disease duration.
Some early studies suggest that anti-TNF-α agents may
increase the risk of malignancies, especially lymphoma
[13-15]. However, this is not supported by a more recent
meta-analysis of clinical trial data or more recent data
from clinical registries [16-18]. Nevertheless, we paid
close attention to the appearance of malignant tumors.
There were four cases of malignant tumors, three of
which led to treatment discontinuation. However, there
were no cases of lymphoma, all four were different tumor
types, and there were no obvious relations between the
incidence of tumors and any of the patient characteris-
tics.
We also paid close attention to the incidence of cardio-
vascular AEs because RA patients are at increased risk
[33]. Cardiovascular events accounted for 4 of 74 treat-
ment discontinuations, and they were the fourth most
common AE overall. They also accounted for two of the
nine deaths. Despite the importance of cardiovascular
events, there is good evidence that anti-TNF-α therapies
reduce the risk in patients with RA to the level in the non-
RA population [33-35].
AEs overall, SAEs, and IRs were most common during
the first 26 weeks of treatment. We found an association
with higher age and the appearance of AEs overall. Also,
higher age was a predictor of SAEs, infections, and dis-
continuation due to a SAE, but the odds ratios were all
close to 1.0. Otherwise, we did not identify significant
risk factors for AEs overall, SAEs, infections, or IRs in this
study.
One of the key aims of this study was to identify rea-
sons for discontinuation in RA patients treated with inf-
liximab. In the evaluable population, the continuation
rate at 74 weeks was 68.7%. This is comparable with most
other studies of daily clinical practice, which have shown
one-year continuation rates between 65% and 73% and
two-year continuation rates between 67% and 75%
[21,36-38]. The continuation rate in the current study
was lower than the one-and two-year rates (91% and 81%,
respectively) in a previous multicenter study carried out
in Belgium [39]. This difference was partly due to the fact
that dose increases were possible in the previous study
but not here. In addition, the current study took place
after etanercept and adalimumab became available, so
that patients had the option of switching to alternative
anti-TNF-α therapies. Thus, patients would have been
more likely in the current study to discontinue treatment
if they or the investigator were uncomfortable with the
AEs or the level of efficacy.
Treatment discontinuations were most frequent during
the first 26 weeks. The AEs most frequently leading to
discontinuation were IRs, followed by infections. Baseline
characteristics, including age, did not appear to predis-
pose patients to discontinuation due to an AE. Higher age
was a significant predictor of discontinuation due to an
SAE, but the odds ratio was close to 1.0. Similarly, Chevil-
lotte-Maillard et al. reported no difference in discontinu-
ation rates (median one-year follow-up) or drug survival
curves between older and younger patients treated with
infliximab [40].
Infections were also most common during the first 26
weeks of the study. This agrees with the findings of the
ARTIS study, where the risk of infection was highest in
the first year [27]. We suspect that this was due to the dis-
continuation of susceptible patients rather than an adap-
tation to the treatment. This is supported by the fact that
discontinuation for any AE was most common during the
first 26 weeks. Moreover, using data from a registry of
British patients, Dixon and colleagues showed that the
risk of serious infection is highest in the first six months
after the initiation of anti-TNF-α therapies and that the
reduction in risk thereafter is associated with physicians
excluding patients considered at high risk [41]. Regard-
less of the reason for the lower risk for infection with
time, some risk is always present, so physicians should
remain vigilant during the course of treatment with inf-
liximab or any other anti-TNF-α therapy.
Prior to beginning the study, we speculated that the use
of corticosteroids would reduce the frequency of IRs and
increase the frequency of infections. However, our analy-
sis showed that the use of corticosteroids was not associ-
ated with a difference in the likelihood of AEs overall,
SAEs, IRs, allergic skin reactions, or infections, nor did it
appear to influence the likelihood of discontinuation due
to AEs or IRs. These results suggest that patients can con-
tinue corticosteroid use during treatment with inflix-
imab, if indicated, without increasing the chance for
discontinuation or occurrence of an AE, including infec-
tions. The results also suggest that corticosteroids do not
prevent infliximab-induced IRs. Notably, all four
reported cases of tuberculosis were in patients taking
corticosteroids at baseline, and all had negative Mantoux
tests at screening. Thus, it is possible that the corticoster-
Delabaye et al. Arthritis Research & Therapy 2010, 12:R121
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tuberculosis infections in these patients by suppressing
their immune systems.
Conclusions
In conclusion, we found that, in RA patients treated with
infliximab and MTX, discontinuations and AEs occur
most frequently during the first 26 weeks of treatment.
The study also emphasizes that physicians should care-
fully monitor patients for the appearance of infections,
including but not limited to tuberculosis and other bacte-
rial infections.
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